Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ABBV

AbbVie (ABBV)

AbbVie Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:ABBV
DateTimeSourceHeadlineSymbolCompany
08/08/202406:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
08/08/202405:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ABBVAbbVie Inc
01/08/202422:23PR Newswire (US)AbbVie Completes Acquisition of Cerevel TherapeuticsNYSE:ABBVAbbVie Inc
30/07/202422:00PR Newswire (US)Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® DayNYSE:ABBVAbbVie Inc
30/07/202420:00IH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:ABBVAbbVie Inc
28/07/202422:05GlobeNewswire Inc.Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)NYSE:ABBVAbbVie Inc
26/07/202416:00PR Newswire (US)AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisNYSE:ABBVAbbVie Inc
25/07/202421:41Edgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
25/07/202421:36PR Newswire (US)AbbVie Reports Second-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
25/07/202420:21IH Market NewsU.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire ExpectationsNYSE:ABBVAbbVie Inc
23/07/202421:02PR Newswire (Canada)AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug AgencyNYSE:ABBVAbbVie Inc
23/07/202421:02PR Newswire (Canada)L'Agence des médicaments du Canada octroie à AbbVie sa toute première recommandation de remboursement à durée limitée pour EPKINLY (MC)NYSE:ABBVAbbVie Inc
12/07/202422:30PR Newswire (US)AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell ArteritisNYSE:ABBVAbbVie Inc
10/07/202422:00PR Newswire (US)AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific OfficerNYSE:ABBVAbbVie Inc
05/07/202422:13IH Market NewsTesla Listed for China’s Government Vehicles; Macy’s Acquisition Offer Raised, and More NewsNYSE:ABBVAbbVie Inc
02/07/202422:00PR Newswire (US)AbbVie to Host Second-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
01/07/202422:00PR Newswire (US)Robert A. Michael Assumes Role as AbbVie Chief Executive OfficerNYSE:ABBVAbbVie Inc
28/06/202416:00PR Newswire (US)AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaNYSE:ABBVAbbVie Inc
27/06/202423:26PR Newswire (US)AbbVie Acquires Celsius TherapeuticsNYSE:ABBVAbbVie Inc
27/06/202422:30PR Newswire (US)Introducing Allē Payment Plans, Powered by CherryNYSE:ABBVAbbVie Inc
27/06/202409:03PR Newswire (US)U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular LymphomaNYSE:ABBVAbbVie Inc
25/06/202422:15PR Newswire (US)AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)NYSE:ABBVAbbVie Inc
21/06/202422:00PR Newswire (US)AbbVie Declares Quarterly DividendNYSE:ABBVAbbVie Inc
20/06/202422:00PR Newswire (US)AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of DirectorsNYSE:ABBVAbbVie Inc
19/06/202408:18PR Newswire (US)U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel DiseaseNYSE:ABBVAbbVie Inc
15/06/202406:08PR Newswire (US)AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" OfferNYSE:ABBVAbbVie Inc
13/06/202421:59PR Newswire (US)AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel DiseaseNYSE:ABBVAbbVie Inc
11/06/202422:00PR Newswire (US)BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant RecipientsNYSE:ABBVAbbVie Inc
06/06/202422:45PR Newswire (US)AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian CancerNYSE:ABBVAbbVie Inc
06/06/202422:30PR Newswire (US)SkinMedica® Celebrates 25 Years of Empowering Radiant SkinNYSE:ABBVAbbVie Inc
 Showing the most relevant articles for your search:NYSE:ABBV